Literature DB >> 25145976

Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications.

Yuka Takahashi1,2, Masayuki Kurosaki2, Nobuharu Tamaki2, Yutaka Yasui2, Takanori Hosokawa2, Kaoru Tsuchiya2, Hiroyuki Nakanishi2, Jun Itakura2, Namiki Izumi1,2.   

Abstract

AIM: To investigate the relation between systemic complications of non-alcoholic fatty liver disease (NAFLD) and non-invasive fibrosis scores.
METHODS: The NAFLD fibrosis score (NFS) and FIB-4 were measured in 1559 people who underwent a complete medical checkup at our hospital and were followed for more than 3 years. Correlation between these scores and prevalence and new incidence rates of diabetes or cerebral-cardiovascular diseases were analyzed.
RESULTS: The 1559 cases were classified into two groups using the low cut-off values of NFS and FIB-4: group 1 (≥low cut-off score with fatty liver) and group 2 (the others). In group 1, the prevalence of diabetes and cerebral-cardiovascular diseases at baseline and additional incidences during the observation period was higher compared with group 2. Diabetes at baseline in group 1 versus group 2 were 31.5% versus 3.1% (NFS, P < 0.0001), 17.0% versus 4.7% (FIB-4, P < 0.0001), and cerebral-cardiovascular diseases at baseline were 7.7% versus 2.3% (NFS, P = 0.002) and 9.0% versus 2.3% (FIB-4, P = 0.0012). New incidences of diabetes were 4.5% versus 1.2% (NFS, P = 0.034) and 3.6% versus 1.2% (FIB-4, P = 0.11), and of cerebral-cardiovascular diseases were 5.0% versus 0.9% (NFS, P = 0.0019) and 5.4% versus 0.9% (FIB-4, P = 0.0034).
CONCLUSION: NFS and FIB-4 are useful to extract cases with high risk of systemic complications of NAFLD in the public.
© 2014 The Japan Society of Hepatology.

Entities:  

Keywords:  FIB-4; cerebral-cardiovascular diseases; diabetes; non-alcoholic fatty liver disease; non-alcoholic fatty liver disease fibrosis score

Year:  2014        PMID: 25145976     DOI: 10.1111/hepr.12405

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  9 in total

1.  Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease.

Authors:  Saumya Jayakumar; Stephen A Harrison; Rohit Loomba
Journal:  Curr Hepatol Rep       Date:  2016-04-21

2.  The impact of non-alcoholic fatty liver disease fibrosis score on cardiac prognosis in patients with chronic heart failure.

Authors:  Tetsuya Takahashi; Tetsu Watanabe; Tetsuro Shishido; Ken Watanabe; Takayuki Sugai; Taku Toshima; Daisuke Kinoshita; Miyuki Yokoyama; Harutoshi Tamura; Satoshi Nishiyama; Takanori Arimoto; Hiroki Takahashi; Tamon Yamanaka; Takuya Miyamoto; Isao Kubota
Journal:  Heart Vessels       Date:  2017-12-29       Impact factor: 2.037

Review 3.  Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.

Authors:  Vasilios G Athyros; Konstantinos Tziomalos; Niki Katsiki; Michael Doumas; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

4.  Testing the ability of the nonalcoholic fatty liver disease fibrosis score to predict 1-year all-cause hospital admission.

Authors:  Trace Heavener; Ahmed Memon; Shamyal Khan; Sam Davis; Lauren Sager; Sharon DeMorrow; Mark Jeffries
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-01-29

Review 5.  Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Rohit Loomba; Namiki Izumi
Journal:  Ann Lab Med       Date:  2020-08-25       Impact factor: 3.464

6.  Fibrosis-4 index at diagnosis is associated with all-cause mortality in patients with microscopic polyangiitis and granulomatosis with polyangiitis.

Authors:  Hee Jin Park; Jun Yong Park; Seung Min Jung; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  BMC Gastroenterol       Date:  2019-06-13       Impact factor: 3.067

7.  Oxidized High-Density Lipoprotein Shows a Stepwise Increase as Fibrosis Progresses in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Kouichi Miura; Naoshi Arai; Rie Goka; Naoki Morimoto; Shunji Watanabe; Norio Isoda; Hironori Yamamoto; Kazuhiko Kotani
Journal:  Antioxidants (Basel)       Date:  2021-02-04

8.  Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease.

Authors:  Giovanni Alejandro Salgado Alvarez; Samanta Mayanin Pinto Galvez; Uriel Garcia Mora; Ana Delfina Cano Contreras; Cristina Durán Rosas; Bryan Adrián Priego-Parra; Arturo Triana Romero; Mercedes Amieva Balmori; Federico Roesch Dietlen; Sophia Eugenia Martinez Vazquez; Ines Osvely Mendez Guerrero; Luis Alberto Chi-Cervera; Raúl Bernal Reyes; Leonardo Alberto Martinez Roriguez; Maria Eugenia Icaza Chavez; Jose Maria Remes Troche
Journal:  World J Hepatol       Date:  2022-08-27

9.  Nonalcoholic Fatty Liver Disease for Identification of Preclinical Carotid Atherosclerosis.

Authors:  Dong Hyun Sinn; Soo Jin Cho; Geum-Youn Gwak; Juhee Cho; Seonhye Gu; Donghyeong Seong; Danbee Kang; Hyunkyoung Kim; Byoung-Kee Yi; Seung Woon Paik
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.